RecruitingNot ApplicableNCT05729607

Vertical Soft Tissue Augmentation With CTG vs ADM

Vertical Soft Tissue Augmentation With Dermal Matrix and Enamel Matrix Derivative vs Connective Tissue Graft for the Treatment of Peri-implant Soft Tissue Dehiscences in the Esthetic Zone: A Randomized, Controlled, Clinical, Trial

Sponsor

Harvard Medical School (HMS and HSDM)

Enrollment

28 participants

Start Date

May 26, 2023

Study Type

INTERVENTIONAL

Conditions

Implant Complication

Summary

The study aims at comparing two different approaches for vertical soft tissue augmentation at implant sites exhibiting soft tissue dehiscences: autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a procedure called Vertical soft tissue augmentation and a procedure called Vertical soft tissue augmentation for people with implant complication. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 99 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.